Brooks Lab Limited

BROOKS NSE Healthcare Pharmaceuticals
₹66.38
+3.96%
Delayed · cached 15 min

Fair value analysis

BROOKS
Brooks Lab Limited
HealthcarePharmaceuticals
₹63.85
Close used for this calculation
₹46.05Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
58/100
Profitability12/25
Returns12/25
Balance Sheet21/25
Efficiency13/25
Growth0/25
Good
Quality radar
58Prof.12/25Ret.12/25Eff.13/25B.Sht21/25Growth0/25

Consensus fair value

₹46.05
Above FV
▼ -27.9% against the close used
Model range ₹26.66 – ₹297.74
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹26.66Fair value₹46.05Bull₹297.74
FairClose
52-week traded range
52W low ₹37.1152W high ₹159.04

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

Brooks Lab Limited closed at ₹63.85, 38.7% above the consensus fair value of ₹46.05 drawn from 7 valuation models.

Financial DNA score 58/100 — Good. P/E of 14.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹37.01
-42.0%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹63.95
+0.2%
√(22.5 × EPS × BVPS)
EPS=8.34, BVPS=21.79 · outside Graham range (P/E 14.6, P/B 2.9) — asset-light, treat as a rough floor
P/E Fair Value
₹297.74
+366.3%
EPS × 35.7x (sector P/E)
EPS=8.34, Sector P/E=35.7x
EV/EBITDA
₹26.66
-58.2%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=90M
Book Value (P/B)
₹59.15
-7.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=21.79, ROE=22%, g=3%, r=10%
Reverse DCF
₹63.85
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -6.1% | Historical: 0%
Margin of Safety
₹99.68
+56.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=132.9, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.